An Australian stem cell and regenerative medicine company

June 11, 2022

Riding the wave with Dr Ross Macdonald

An avid surfer of over 50 years, Ross has a vested interest in helping us live better for longer, especially protecting our joints. In early June he spoke with the Australian Financial Review about his love of surfing, and how he finds peace of mind and strategic clarity while riding waves

June 01, 2022

Ross sits down with Bulls n Bears following FDA Phase 2 trial clearance

Managing Director Dr Ross Macdonald spoke to Matt Birney on the Bulls N’ Bears Report about the FDA clearing Cynata’sInvestigational New Drug (IND) application for a Phase 2 acute graft versus host disease (aGvHD) trial adding yet another indication to Cynata's broad and robust clinical pipeline. 

Listen to the interview here

May 26, 2022

Cynata gets the green light for Phase 2 aGVHD trial

In exciting news, the US FDA cleared Cynata’s Investigational New Drug (IND) application for a Phase 2 clinical trial of CYP-001 in patients with acute graft versus host disease (aGvHD). The planned Phase 2 clinical trial will seek to recruit approximately 60 patients with high risk aGvHD, at clinical centres in several countries, including the US and Australia. FDA clearance is a major achievement and valuation milestone for the Company.

The stock was up 10 per cent following the announcement, read the full details on The Australian:

April 24, 2022

Q&A with CMO Jolanta Airey

Joining Cynata as Chief Medical Officer in October 2021, Dr Jolanta Airey sat down with ValiantCEO for International Women’s Day to discuss her motivations, her career journey to date and her advice for women in STEM. If you’d like to be inspired, the full interview is here: 

Read Article

March 03, 2022

China opens up to Cynata through new patent

In late February, Cynata received a notice of Decision to Grant from the State Intellectual Property Office of the People’s Republic of China (SIPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell (MSC) technology (scroll to after the table): 

Read Article